1. Home
  2. PHIN vs HRMY Comparison

PHIN vs HRMY Comparison

Compare PHIN & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PHINIA Inc.

PHIN

PHINIA Inc.

N/A

Current Price

$73.98

Market Cap

2.3B

Sector

N/A

ML Signal

N/A

Logo Harmony Biosciences Holdings Inc.

HRMY

Harmony Biosciences Holdings Inc.

N/A

Current Price

$33.18

Market Cap

2.2B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PHIN
HRMY
Founded
2023
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.2B
IPO Year
2023
2020

Fundamental Metrics

Financial Performance
Metric
PHIN
HRMY
Price
$73.98
$33.18
Analyst Decision
Buy
Buy
Analyst Count
5
12
Target Price
★ $84.40
$48.08
AVG Volume (30 Days)
346.9K
★ 1.1M
Earning Date
10-29-2026
11-04-2026
Dividend Yield
★ 1.65%
N/A
EPS Growth
★ 84.09
7.97
EPS
★ 3.79
2.63
Revenue
N/A
★ $868,453,000.00
Revenue This Year
$4.85
$18.31
Revenue Next Year
$3.11
$14.97
P/E Ratio
$19.19
★ $12.56
Revenue Growth
N/A
★ 21.51
52 Week Low
$51.38
$25.90
52 Week High
$86.94
$43.49

Technical Indicators

Market Signals
Indicator
PHIN
HRMY
Relative Strength Index (RSI) 68.68 33.62
Support Level $69.02 $32.53
Resistance Level $81.40 $33.00
Average True Range (ATR) 2.68 1.46
MACD 0.65 -0.13
Stochastic Oscillator 100.00 9.96

Price Performance

Historical Comparison
PHIN
HRMY

About PHIN PHINIA Inc.

Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, it generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Share on Social Networks: